Why Biofilm Matters in Diabetic Foot Care
Diabetic foot ulcers (DFUs) are among the most serious and treatment-resistant complications of diabetes, affecting an estimated 12–25% of people with the condition at some point during their lifetime. Despite advances in wound care, a substantial proportion of these ulcers fail to progress through normal healing phases — becoming chronic, recurrent, and prone to infection. One factor increasingly recognized as central to this pattern is the formation of bacterial biofilm within the wound bed.
Biofilm is not simply a heavy bacterial load. It is a structured, community-based mode of bacterial existence in which microorganisms attach to wound surfaces, encase themselves in a self-produced extracellular matrix, and become dramatically more resistant to both host immune defenses and antimicrobial agents. Understanding biofilm — how it forms, how it disrupts healing, and how it can be targeted — is essential to improving outcomes in diabetic foot wound care.
What Is Biofilm and Why Does It Develop in Diabetic Wounds?
Biofilm develops when free-floating (planktonic) bacteria adhere to a surface, replicate, and produce a protective polysaccharide matrix known as the extracellular polymeric substance (EPS). Once established, biofilm bacteria are estimated to be 100 to 1,000 times more resistant to antibiotics than their planktonic counterparts — a consequence of reduced antibiotic penetration, altered metabolic states within the biofilm, and horizontal gene transfer that accelerates resistance development.
The diabetic wound environment is particularly conducive to biofilm formation. Chronic hyperglycemia impairs neutrophil and macrophage function, reduces local tissue oxygen tension, and promotes the glycation of key immune proteins. These changes suppress the normal bacterial clearance mechanisms that would otherwise prevent biofilm establishment. A 2024 systematic review published in Frontiers in Clinical Diabetes and Healthcare identified impaired innate immunity, microvascular disease, and peripheral neuropathy — all hallmarks of diabetes — as primary facilitators of biofilm-driven infection in DFUs (Lepäntalo et al., 2024).
The microbial composition of DFU biofilms is typically polymicrobial. Staphylococcus aureus is the most frequently identified organism in Western populations, while Pseudomonas aeruginosa predominates in some tropical and Asian settings. Gram-negative anaerobes and fungi may also contribute, and the synergistic interactions between species within a polymicrobial biofilm can further amplify virulence and treatment resistance.
How Biofilm Impairs Wound Healing
Biofilms are now implicated in approximately 60% of chronic wounds, including DFUs. Their presence shifts the wound from a normal acute inflammatory phase into a state of persistent, low-grade inflammation that prevents progression to the proliferative and remodeling phases of healing. A 2025 review in the Journal of Clinical Medicine described how biofilm-associated chronic inflammation drives sustained matrix metalloprotease (MMP) activity, degrading growth factors and extracellular matrix components essential for tissue repair (Percival et al., 2025).
Clinically, biofilm-associated DFUs often exhibit characteristic features: pale, friable granulation tissue; recurrent slough despite debridement; wound malodor disproportionate to visible signs of infection; failure to reduce in size by at least 50% over four weeks of standard care; and hypergranulation at wound margins. These clinical signs, while not confirmatory, should heighten suspicion of established biofilm and prompt a reassessment of the management approach.
A 2024 review in Advances in Skin & Wound Care by Astrada, Nakagami, and Sanada highlighted the significant diagnostic challenge posed by biofilm, noting that standard wound cultures may fail to detect biofilm-forming organisms accurately because conventional swab sampling preferentially captures planktonic bacteria rather than biofilm communities embedded in tissue.
Emerging Approaches to Biofilm Detection and Management
Accurate biofilm identification is an area of active clinical investigation. Point-of-care fluorescence imaging devices, such as MolecuLight, can detect bacterial fluorescence signatures in the wound bed in real time, providing clinicians with spatial information about bacterial burden before debridement. A pilot RCT published in Diabetes Care demonstrated that fluorescence-guided debridement resulted in more complete bacterial load reduction compared to standard-of-care debridement alone (Serena et al., 2022).
A randomised controlled trial published in the Journal of Wound Care in 2024 evaluated a biofilm detection-guided management protocol in patients with DFUs. The intervention combined wound blotting to detect biofilm with the addition of antimicrobial dressings and enhanced wound cleansing based on those results. Compared to standard care, the biofilm-guided protocol produced significantly greater improvements in wound healing and biofilm elimination, particularly after two weeks of weekly treatment — providing clinical evidence that structured biofilm assessment can improve outcomes in practice.
Management of established biofilm in DFUs requires a multi-pronged approach. Sharp or surgical debridement remains the most effective immediate method of physically disrupting biofilm structure; its repeated application at regular intervals is considered essential, as biofilm can reform within 24–72 hours of disruption. Antimicrobial dressings — including those containing cadexomer iodine, silver, dialkylcarbamoyl chloride (DACC), or medical-grade honey — can suppress biofilm reformation between debridements. Super-oxidized solutions and hypochlorous acid formulations have demonstrated biofilm-disrupting properties in several in vitro and early clinical studies, with a 2025 review in Cardiovascular Diabetology identifying them as promising adjuncts for wound bed preparation in biofilm-burdened DFUs, particularly in older patients with impaired immune responses (López-Valverde et al., 2025).
Systemic antibiotic therapy, while essential for clinically infected wounds, has limited efficacy against established biofilm and should not be relied upon as the primary anti-biofilm intervention in the absence of signs of systemic or deep tissue infection.
Clinical Takeaways
Biofilm represents one of the most significant — and frequently underrecognized — barriers to healing in chronic diabetic foot ulcers. Its presence should be suspected in any DFU that fails to respond to standard care over four weeks, exhibits recurrent slough or friable tissue, or demonstrates disproportionate bacterial odor. Effective biofilm management requires regular sharp debridement, selection of antimicrobial dressings appropriate to the biofilm burden, and in select cases, adjunctive biofilm-disrupting agents. As clinical tools for biofilm detection continue to improve, more targeted and timely interventions should become feasible in routine practice.
References
- Lepäntalo A et al. “A systematic review of diabetic foot infections: pathogenesis, diagnosis, and management strategies.” Frontiers in Clinical Diabetes and Healthcare. 2024. doi:10.3389/fcdhc.2024.1393309
- Percival SL et al. “Biofilms and Chronic Wounds: Pathogenesis and Treatment Options.” Journal of Clinical Medicine. 2025;14(21):7784. doi:10.3390/jcm14217784
- Astrada A, Nakagami G, Sanada H. “Challenges in Biofilm Identification in Diabetic Foot Infections: Review of Literature.” Advances in Skin & Wound Care. 2024. doi:10.1177/15347346241273112
- Wound blotting-guided biofilm detection in DFUs: a randomised controlled trial. Journal of Wound Care. 2024. doi:10.12968/jowc.2024.0051
- Serena TE et al. “The Use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial.” Diabetes Care. 2022;45(7):1601–1607.
- López-Valverde N et al. “Aging, biofilms, and diabetic foot ulcers: disrupting chronic infections with super-oxidized solutions.” Cardiovascular Diabetology – Endocrinology Reports. 2025. doi:10.1186/s40842-025-00261-5
Comments
